Multiple Myeloma

Multiple myeloma is a rare blood cancer characterized by the uncontrolled proliferation of abnormal plasma cells in the bone marrow, leading to bone damage, anemia, fatigue, and kidney dysfunction due to excess antibody production. It results from the transformation of healthy plasma cells into malignant ones that crowd out normal blood cell production, causing symptoms such as persistent bone pain, weakness, and shortness of breath. The disease may present as multiple tumors throughout the body, requiring careful monitoring and management. While incurable, treatments including chemotherapy, radiation, and stem cell transplantation can help control progression and alleviate symptoms.

References:

[1]. Multiple Myeloma. sciencedirect.

Multiple Myeloma (1):

Targets:	Drug-Linker Conjugates for ADC (1)

Cat. No.	Product Name	CAS No.	Purity	Chemical Structure

HY-P11268

Tismanitin maleimide	2311860-86-1
Tismanitin maleimide (pamlectabart tismanitin; HDP-101) is a linker-cargo component of an antibody-drug conjugate (ADC). Tismanitin maleimide is covalently bound to a monoclonal antibody (mAb) through a cleavable linker, forming a targeted anti-cancer therapy. Tismanitin maleimide can be used for research on multiple myeloma.

Name
Email *

	Sorry, but the email address you supplied was invalid.